About Pyroglutamylated RF-amide peptide receptor
Pyroglutamylated RF-amide peptide receptor (QRFPR) is a protein
from Homo sapiens identified by UniProt accession
Q96P65, 431 residues long.
MolForge cross-references it against 0 known binders and
118 disease associations.
Target properties
| Protein name | Pyroglutamylated RF-amide peptide receptor |
| UniProt accession | Q96P65 |
| Gene | QRFPR |
| Organism | Homo sapiens |
| Length | 431 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (118)
Diseases linked to this target (Open Targets).
- body weight · score 0.34
- autoimmune thyroid disease · score 0.29
- type 1 diabetes mellitus · score 0.29
- glioblastoma multiforme · score 0.26
- metabolite measurement · score 0.26
- breast adenocarcinoma · score 0.25
- protein measurement · score 0.25
- head and neck squamous cell carcinoma · score 0.20
- cutaneous melanoma · score 0.18
- lung adenocarcinoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96P65-F1 | alphafold | PREDICTED | 78.76 | — |
Amino-acid sequence (431 residues)
MQALNITPEQ FSRLLRDHNL TREQFIALYR LRPLVYTPEL PGRAKLALVL TGVLIFALAL FGNALVFYVV TRSKAMRTVT NIFICSLALS DLLITFFCIP VTMLQNISDN WLGGAFICKM VPFVQSTAVV TEILTMTCIA VERHQGLVHP FKMKWQYTNR RAFTMLGVVW LVAVIVGSPM WHVQQLEIKY DFLYEKEHIC CLEEWTSPVH QKIYTTFILV ILFLLPLMVM LILYSKIGYE LWIKKRVGDG SVLRTIHGKE MSKIARKKKR AVIMMVTVVA LFAVCWAPFH VVHMMIEYSN FEKEYDDVTI KMIFAIVQII GFSNSICNPI VYAFMNENFK KNVLSAVCYC IVNKTFSPAQ RHGNSGITMM RKKAKFSLRE NPVEETKGEA FSDGNIEVKL CEQTEEKKKL KRHLALFRSE LAENSPLDSG H
Explore Pyroglutamylated RF-amide peptide receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets